Metraipolis › archive › dc_9911d402e5ec
Retreatment and Reactivation Rates Following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity: A Systematic Review and… — Europe PMC PMID:41054667
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41054667
- DOI
- 10.7759/cureus.91652
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T02:44:49.174Z
- SHA-256 of the archived text
266de1517d1e50059be2e982706282e70013fafacdf86bd50389e6e8c8ede3f8- Stable URL of this page
https://metraipolis.com/documento/dc_9911d402e5ec
How to cite
Retreatment and Reactivation Rates Following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity: A Systematic Review and… — Europe PMC PMID:41054667 — Europe PMC (en), https://europepmc.org/article/MED/41054667 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9911d402e5ec (Metraipolis archive dc_9911d402e5ec, sha256 266de1517d1e50059be2e982706282e70013fafacdf86bd50389e6e8c8ede3f8)
BibTeX
@misc{dc9911d402e5ec,
title = {Retreatment and Reactivation Rates Following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity: A Systematic Review and… — Europe PMC PMID:41054667},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41054667},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9911d402e5ec; sha256 266de1517d1e50059be2e982706282e70013fafacdf86bd50389e6e8c8ede3f8},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41054667. Agents can read the archived copy with the MCP tool read_document.